Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 176

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 176
---
 on assumptions that may prove to be incorrect or require adjustment as a result of business decisions, and Kineta could utilize its available capital resources sooner than it currently expects. Kineta’s future capital requirements will depend on many factors, some of which are outside of its control, including:

| • |     | the initiation, design, progress, timing, costs and results of drug discovery, preclinical studies and clinical trials of Kineta’s product candidates; |

| • |     | the number and characteristics of product candidates that Kineta pursues; |

| • |     | the number of clinical trials needed for regulatory approvals from the FDA, the European Commission (based on recommendation from the EMA), and any other regulatory authority; |

| • |     | the length of Kineta’s clinical trials, including, among other things, as a result of delays in enrollment, difficulties enrolling sufficient subjects or delays or difficulties in clinical trial site initiations; |

| • |     | increased costs associated with conducting Kineta’s clinical trials; |

| • |     | successfully complete ongoing pre-clinical studies and clinical trials; |

| • |     | the outcome, timing and costs of seeking regulatory approvals from the FDA, the European Commission, and any other regulatory authority; |

| • |     | the costs of manufacturing Kineta’s product candidates, in particular for clinical trials in preparation for marketing approval and in preparation for commercialization; |

| • |     | the costs of any third-party products used in Kineta’s combination clinical trials that are not covered by such third party or other sources; |

| • |     | the costs associated with hiring additional personnel and consultants as Kineta’s preclinical, manufacturing and clinical activities increase; |

| • |     | the receipt of marketing approval and revenue received from any commercial sales of any of Kineta’s product candidates, if approved; |

| • |     | the cost of commercialization activities for any of Kineta’s product candidates, if approved, including marketing, sales and distribution costs; |

| • |     | the emergence of competing therapies and other adverse market developments; |

| • |     | the ability to establish and maintain strategic collaboration, licensing or other arrangements and the financial terms of such agreements; |

| • |     | the extent to which Kineta in-licenses or acquires other products and technologies; |

| • |     | the amount and timing of any payments Kineta may be required to make pursuant to its current or future license agreements; |

| • |